ArticleInfectious diseases and therapy2015
Tedizolid Phosphate: a Next-Generation Oxazolidinone.
Article in Infectious diseases and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 77 citations in OpenAlex.
- Green stability-indicating RP-HPLC method for simultaneous bioanalysis of tedizolid phosphate and ciprofloxacin in human plasma.Scientific reports · 2026Article
- Solvent-Assisted Catalysis: Water Promotes Ring Closure Formation of 2‑Oxazolidinone from Amino Acid DerivedACS organic & inorganic Au · 2025Article
- Linezolid in the Focus of Antimicrobial Resistance ofInternational journal of molecular sciences · 2025Review
- Redesigning oxazolidinones as carbonic anhydrase inhibitors against vancomycin-resistant enterococci.European journal of medicinal chemistry · 2025Article
- Article
- One-pot synthesis of pyrazolo[4,3-RSC advances · 2023Article
- The Role of Five-Membered Heterocycles in the Molecular Structure of Antibacterial Drugs Used in Therapy.Pharmaceutics · 2023Review
- New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.Clinical microbiology reviews · 2023Review
- In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race.International journal of molecular sciences · 2023Review
- Molecular Characterization ofFrontiers in microbiology · 2021Article
- Development and Clinical Application of Phosphorus-Containing Drugs.Medicine in drug discovery · 2020Review
- Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches.Molecules (Basel, Switzerland) · 2020Review
- A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.Infectious diseases and therapy · 2020Article
- Antimicrobial resistance in methicillin-resistantAntimicrobial agents and chemotherapy · 2019Review
- Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy.Core evidence · 2019Article
- Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.The Journal of antimicrobial chemotherapy · 2017Article
- Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Expert opinion on drug metabolism & toxicology · 2017Review
- Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.Drug design, development and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of multidrug-resistant Gram-positive infections continues to challenge clinicians as the emergence of new resistance mechanisms outpaces introduction of novel antimicrobial agents. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus spp. Tedizolid has consistently shown potency advantages over linezolid against Gram-positive microorganisms including those with reduced susceptibility to linezolid. Of particular significance, minimum inhibitory concentrations of tedizolid appear to be largely unaffected by the chloramphenicol-florfenicol resistance (cfr) gene, which has been implicated in a number of published linezolid-resistant organism outbreaks. Tedizolid phosphate also has been found to have a favorable pharmacokinetic profile allowing for once-daily dosing in both oral and intravenous forms. Potency and pharmacokinetic advantages have allowed for lower total daily doses of tedizolid, compared to linezolid, being needed for clinical efficacy in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The decreased total drug exposure produced may in part be responsible for a decrease in the observed adverse effects including thrombocytopenia. Tedizolid phosphate is currently indicated for the treatment of ABSSSI and under investigation for the treatment of nosocomial pneumonia. Although much of the role of tedizolid remains to be defined by expanding clinical experience, tedizolid is likely a welcomed addition to the mere handful of agents available for the treatment of multidrug-resistant Gram-positive infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.